**Biocon Ltd to Fully Integrate Biocon Biologics in $5.5 Billion Deal**
Biocon Ltd has announced plans to fully integrate Biocon Biologics Ltd as a wholly owned subsidiary in a deal valued at $5.5 billion. The acquisition will see Biocon purchasing the remaining stake in Biocon Biologics from Serum Institute Life Sciences, Tata Capital Growth Fund II, and Activ Pine LLP through a share swap, offering 70.28 Biocon shares for every 100 Biocon Biologics shares, priced at ₹405.78 per share. Additionally, Biocon will acquire the remaining stake held by Mylan Inc. (Viatris) for a total of $815 million, which includes $400 million in cash and a share swap of 61.70 Biocon shares for every 100 Biocon Biologics shares, also at ₹405.78 per share. The integration is expected to be finalized by March 31, 2026.
In May 2025, Biocon established a strategy committee to explore potential merger or public listing options for its biologics division. After thorough evaluation of strategic alignment, market dynamics, and shareholder value, the committee determined that full integration with Biocon Ltd would provide the most efficient and value-enhancing path forward.
Biocon’s board has also approved a plan to raise up to ₹4,500 crore through a qualified institutional placement (QIP), pending shareholder approval. The funds raised will primarily be used for the cash component payable to Viatris.
Kiran Mazumdar Shaw, executive chairperson of Biocon, emphasized that while a public listing for the biologics unit was previously considered, the merger would unlock greater value. She noted that market perceptions regarding acquisition-related leverage have negatively impacted Biocon Ltd’s valuation, leading to a holding company discount that does not accurately reflect the performance of Biocon Biologics.
In 2022, Biocon Biologics acquired Viatris’ global biosimilars portfolio for $3.3 billion and currently carries acquisition-related debt of approximately $1.2 billion. The merger is expected to strengthen the company’s balance sheet, improving its consolidated debt-to-Ebitda ratio from 4.3x in 2020 to 2.5x as of September 2025. Mazumdar stated that this ratio will continue to decline, enhancing the company’s financial robustness and enabling further investments in product development.
**FAQ**
*What is the significance of Biocon’s integration of Biocon Biologics?*
The integration is expected to enhance shareholder value by eliminating the holding company discount and improving the overall financial health of Biocon, allowing for more strategic investments in product development.
